Acquisition AgreementRoche announced its intention to acquire Poseida for $9 per share in cash and an additional $4 per share CVR, enhancing shareholder value.

Clinical PerformanceP-BCMA-ALLO1 cells achieved an impressive 91% overall response rate in heavily pretreated multiple myeloma patients, indicating strong clinical performance.

Regulatory ProgressPoseida recently received RMAT designation for P-BCMA-ALLO1 for 3rd-line+ relapsed/refractory multiple myeloma patients, highlighting regulatory progress.

Bears Say

Clinical DevelopmentThe development of P-CD19CD20-ALLO1 in autoimmune disease is dependent on Poseida's CellRx, which could fail in the clinic.

Financial PerformancePoseida will likely require additional capital, indicating potential financial challenges.

Stock RatingThe rating on PSTX is downgraded to Neutral from Buy, with a new price target lowered to $9 from $20.

---

Financials

Annual

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

0.43% Insiders

17.24% Mutual Funds

14.63% Other Institutional Investors

79.14% Public Companies and Individual Investors

Detailed Ownership Overview >

Risk Analysis

Main Risk Category

Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Detailed Risk Analysis >

Website Traffic

Sorry, No Data Available

There is no website visitor data available for this stock.

---

PSTX FAQ

What was Poseida Therapeutics, Inc.’s price range in the past 12 months?

Poseida Therapeutics, Inc. lowest stock price was $1.87 and its highest was $9.67 in the past 12 months.

What is Poseida Therapeutics, Inc.’s market cap?

Poseida Therapeutics, Inc.’s market cap is $925.92M.

When is Poseida Therapeutics, Inc.’s upcoming earnings report date?

Poseida Therapeutics, Inc.’s upcoming earnings report date is Mar 06, 2025 which is in 47 days.

How were Poseida Therapeutics, Inc.’s earnings last quarter?

Poseida Therapeutics, Inc. released its earnings results on Nov 07, 2024. The company reported $0.21 earnings per share for the quarter, beating the consensus estimate of -$0.418 by $0.628.

Is Poseida Therapeutics, Inc. overvalued?

According to Wall Street analysts Poseida Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Poseida Therapeutics, Inc. pay dividends?

Poseida Therapeutics, Inc. does not currently pay dividends.

What is Poseida Therapeutics, Inc.’s EPS estimate?

Poseida Therapeutics, Inc.’s EPS estimate is -0.5.

How many shares outstanding does Poseida Therapeutics, Inc. have?

Poseida Therapeutics, Inc. has 97,465,000 shares outstanding.

What happened to Poseida Therapeutics, Inc.’s price movement after its last earnings report?

Poseida Therapeutics, Inc. reported an EPS of $0.21 in its last earnings report, beating expectations of -$0.418. Following the earnings report the stock price went up 5.119%.

Which hedge fund is a major shareholder of Poseida Therapeutics, Inc.?

Currently, no hedge funds are holding shares in PSTX

---

Poseida Therapeutics, Inc. Stock Smart Score

Unlock Smart Score

Fundamentals

Return on Equity

-57.63%

Trailing 12-Months

Asset Growth

-2.87%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Poseida Therapeutics, Inc.

Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumors.

---